1. Repositório Aberto da Universidade do Porto
  2. ISPUP - Instituto de Saúde Pública
  3. ISPUP - Artigo em Revista Científica Internacional
Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/154385
Registo completo
Campo DCValorIdioma
dc.creatorStengaard, AR
dc.creatorRaben, D
dc.creatorLeite, RB
dc.creatorSeyler, T
dc.creatorLazarus, JV
dc.creatorLambert, J
dc.creatorCollins, B
dc.creatorAttawell, K
dc.creatorRaahauge, A
dc.creatorRockstroh, JK
dc.creatorSimões, D
dc.date.accessioned2023-11-14T12:03:56Z-
dc.date.available2023-11-14T12:03:56Z-
dc.date.issued2022
dc.identifier.issn0956-4624
dc.identifier.issn1758-1052
dc.identifier.urihttps://hdl.handle.net/10216/154385-
dc.description.abstractWe present the outcomes of the HepHIV 2021 Lisbon & virtual conference held on 5-7 May 2021, including a Call to Action addressing policy and practice implications in the field of earlier and integrated testing for HIV, viral hepatitis, STI and TB and in light of lessons learned from the COVID-19 pandemic. Conference presentations showed that combination prevention and integrated testing and care models for multiple infectious diseases are necessary and feasible in diverse settings. Successful examples of service and system adaptations developed to mitigate impact of the pandemic were shared. Aiming to ensure greater equity in health in current and future health policies and programmes and address the adverse effects of COVID-19, we must learn from the many innovative approaches to service delivery developed in response to the pandemic, many of which have the potential to reach people whose needs were not met by existing models. © The Author(s) 2022.
dc.description.sponsorshipFunding text 1: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The HepHIV 2021 Lisbon & virtual Conference received financial support from the EuroTEST Initiative which received sponsorship funds for the conference from Gilead Sciences, Merck MSD and ViiV Healthcare. The conference was co-funded by the 3rd Health Programme of the European Union under grant agreement no 761319 through the Joint Action INTEGRATE. The funders had no input into the content of the conference and no role in the article preparation and decision to publish the manuscript.; Funding text 2: This article was written by the authors on behalf of the HepHIV 2021 Conference Organising Committee and the EuroTEST Steering Committee. HepHIV 2021 Conference Organising Committee: Anastasia Pharris (European Centre for Disease Prevention and Control (ECDC)); Ann-Isabelle von Lingen (European AIDS Treatment Group (EATG)); Anne Bergenström (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)); Antons Mozalevskis (WHO Regional Office for Europe); Ben Collins (ReShape/International HIV Partnerships); Brian Gazzard (Chelsea & Westminster Hospital); Cary James (World Hepatitis Alliance); Daniel Simões (University of Porto & CoalitionPLUS & GAT); Eberhard Schatz (Correlation Network); Elena Vovc (WHO Regional Office for Europe); Erika Duffel (ECDC); Isabel Aldir (Directorate General for Health of Portugal); Joana Bettencourt (Directorate General for Health of Portugal); Jeffrey Lazarus (ISGlobal); John de Wit (Utrecth University); Jordi Casabona (CEEISCAT); Jürgen Rockstroh (University of Bonn); Lella Cosmaro (Lila Milano); Nicole Seguy (WHO Regional Office for Europe); Nikos Dedes (EATG & Positive Voice); Ricardo Baptista Leite (Global Parliamentarians Network to End Infectious Diseases (UNITE)); Teymur Noori (ECDC); Thomas Seyler (EMCDDA); Tom Platteau (Antwerp Institute of Tropical Medicine); Valerie Delpech (Public Health England); Victoria Grandsoult (UNITE). EuroTEST Steering Committee: Anders Sönnerborg (Karolinska University Hospital); Ann K. Sullivan (Chelsea & Westminster Hospital); Ann-Isabelle von Lingen (EATG); Brian Gazzard (Chelsea & Westminster Hospital); Brian West (EATG); Cary James (World Hepatitis Alliance); Daniel Simões (University of Porto & CoalitionPLUS & GAT); Daniela Rojas Castro (Coalition PLUS); Francesco Negro (University Hospitals Geneva & European Association for the Study of the Liver (EASL)); Igor Karpov (Belarus State Medical University); Jack S. Lambert (University College Dublin (UCD)); Jeffrey V Lazarus (ISGlobal); Jens Lundgren (Centre of Excellence for Health, Immunity and Infections (CHIP), University of Copenhagen); John de Wit (Utrecth University); Jordi Casabona (CEEISCAT); Jürgen Rockstroh (University of Bonn); Lella Cosmaro (Lila Milano); Liudmyla Maistat (Medicines Patent Pool); Mojca Matičič (University Medical Centre Ljubljana); Nikos Dedes (EATG & Positive Voice); Nino Tsereteli (Tanadgoma); Rajul Patel (Southampton University Hospitals & International Union against Sexually Transmitted Infections (IUSTI)); Tom Platteau (Antwerp Institute of Tropical Medicine); Valerie Delpech (Public Health England); Yazdan Yazdanpanah (ANRS Maladies Infectieuses Emergentes). Observers to the EuroTEST Steering Committee: Anastasia Pharris, Erika Duffel and Teymur Noori (ECDC); Antons Mozalevskis, Elena Vovc and Nicole Seguy (WHO Regional Office for Europe); Dagmar Hedrich (EMDCCA). The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The HepHIV 2021 Lisbon & virtual Conference received financial support from the EuroTEST Initiative which received sponsorship funds for the conference from Gilead Sciences, Merck MSD and ViiV Healthcare. The conference was co-funded by the 3rd Health Programme of the European Union under grant agreement no 761319 through the Joint Action INTEGRATE. The funders had no input into the content of the conference and no role in the article preparation and decision to publish the manuscript.
dc.language.isoeng
dc.publisherSAGE Publications
dc.relation.ispartofInt J STD AIDS. 2022 Sep;33(10):943-948. doi: 10.1177/09564624221107464. Epub 2022 Jul 15.
dc.rightsrestrictedAccess
dc.titleA call to action to reclaim focus on testing and early treatment for HIV, viral hepatitis, sexually transmitted infections and tuberculosis
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Saúde Pública da Universidade do Porto
dc.identifier.doi10.1177/09564624221107464
dc.relation.publisherversionhttps://journals.sagepub.com/doi/10.1177/09564624221107464
Aparece nas coleções:ISPUP - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
stengaard-ijstda-2022-ARCI.pdf
  Restricted Access		2.51 MBAdobe PDFVer/Abrir
Mostrar registo em formato simples Recomendar este registo Ver estatísticas


Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.